Novartis (NVS)

[Inoviorulez]

https://seekingalpha.com/article/4089618-amgen-novartis-first-mover-advantage-must

[malt66]

Sell short this crap along with other big pharma...


Why...?

Either they reprice, face a major collapse in US GDP, or Trump can use executive order violations of 15 USC Chapter 1

https://market-ticker.org/akcs-www?post=232235

[DewDiligence]

NVS 2Q17 CC slides:

https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/q2-2017-ir-presentation.pdf

[Inoviorulez]

https://seekingalpha.com/article/4087475-novartis-wins-fda-panel-backing-new-car-t-therapy-treatment

[DewDiligence]

NVS’ own PR on CTL019 ODAC panel:

https://www.sec.gov/Archives/edgar/data/1114448/000117184317004057/f6k_071217.htm

[DewDiligence]

FDA approves Tafinlar+Mekinist for BRAF-V600E NSCLC: #msg-132422635.

[DewDiligence]

Ilaris reduces MACE in secondary-prevention setting: #msg-132398529.

[DewDiligence]

RTH258 non-inferior to Eylea with less-frequent injections: #msg-132328161.

[DewDiligence]

EU approves NVS’ Rituxan FoB, called Rixathon:

https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-rixathonr-biosimilar-rituximab-treat-blood

This is the second Rituxan FoB in Europe; Celltrion's Truxima was the first.

[DewDiligence]

NVS “Meet the Management” Investor Day slides:

#msg-131777804

[DewDiligence]

CHMP approves Zykadia in first-line ALK+ NSCLC:

https://finance.yahoo.com/news/chmp-backs-novartiss-zykadia-first-123844663.html

In the US, the PDUFA date for this indication is 8/22/17.

[PStockPickz]

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555778.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

[DewDiligence]

NVS 1Q17 CC slides:

https://www.novartis.com/sites/www.novartis.com/files/q1-2017-ir-presentation.pdf

[DewDiligence]

NVS could take $15-25B loss on Alcon sale:

https://www.bloomberg.com/gadfly/articles/2017-04-20/novartis-alcon-sale-will-take-a-bargain-price

[DewDiligence]

NVS, AGN collaborate on phase-2b for NASH combo: #msg-130568056.

[DewDiligence]

NVS licenses dry-eye drug candidate from (private) Lubris, LLC: #msg-130284224.

[DewDiligence]

Serelaxin fails revamped phase-3 trial in acute HF: #msg-129752197.

[DewDiligence]

FDA approves NVS’ Kisqali (f/k/a LEE011) for first-line HR+/HER2- breast cancer:

https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-lee011-receives-fda-approval-first-line-treatment

The main competitor for Kisqali is PFE’s Ibrance.

[trendmkr]

Novartis AG (ADR) (NYSE:NVS) Fined And Some Products To Be Temporarily Suspended In South Korea https://marketexclusive.com/novartis-ag-adr-nysenvs-fined-products-temporarily-suspended-south-korea/78526/?icd1

[trendmkr]

Novartis AG (NYSE:NVS) Greater Use Of Technology In Transforming Medical Education https://marketexclusive.com/glaxosmithkline-plc-nysegsks-two-drug-cocktail-aim-reduce-number-pills-hiv-patients-take-daily/72033/?icd1

[DewDiligence]

Some info about NVS’ RTH258 for AMD: #msg-128240149.

[DewDiligence]

NVS CC slides…

4Q16 results:
https://www.novartis.com/sites/www.novartis.com/files/q4-2016-ir-presentation.pdf

Pipeline development:
https://www.novartis.com/sites/www.novartis.com/files/q4-2016-ir-presentation-development.pdf

Pipeline research:
https://www.novartis.com/sites/www.novartis.com/files/q4-2016-ir-presentation-research.pdf

[DewDiligence]

NVS inks two deals…

CNAT: #msg-127298914
Encore Vision: #msg-127306395

[Ecomike]

Down nearly 4% in one day on good earnings news. Why?

[DewDiligence]

NVS 3Q16 CC slides:

https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/q3-2016-ir-presentation.pdf

[DewDiligence]

NVS’ LEE011 data impress in first-line HR+/HER2- breast cancer:

#msg-125671020

[DewDiligence]

NVS presents phase-3 data in SPMS:

https://www.novartis.com/news/media-releases/novartis-baf312-reduces-risk-disability-progression-pivotal-phase-iii-study?hootPostID=cfa242079cd3be03006662ed67970b9c

NVS announced three weeks ago that this trial hit its primary endpoint (#msg-124762084).

[DewDiligence]

NVS reduces MNTA stake via 10b5-1 plan: #msg-124870976.

[DewDiligence]

What will NVS do about AMGN's Enbrel patent that runs until 2028?

[DewDiligence]

FDA approves NVS’ Enbrel FoB, but... #msg-124870707.

[DewDiligence]

NVS hits phase-3 primary endpoint in SPMS:

https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients

Novartis today announced the Phase III EXPAND study, evaluating the efficacy and safety of oral, once-daily, BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), met its primary endpoint of a reduction in the risk of disability progression, compared with placebo. The EXPAND study represents the largest randomized, controlled study in SPMS to date.

[venturecapp]

Novartis AG Licenses LGT209 To Cyon Therapeutics, Teams Up With KRCS http://marketexclusive.com/novartis-ag-nysenvs-licenses-lgt209-cyon-therapeutics-inc-teams-krcs/24842/?icd1

[DewDiligence]

NVS’ recent-launch successes—Cosentyx yes, Entresto no:

http://www.bloomberg.com/news/articles/2016-07-19/novartis-profit-declines-as-competition-hurts-cancer-drug-sales

[DewDiligence]

FDA rejects NVS' Enbrel FoB: #msg-123963130.

[DewDiligence]

NVS 2Q16 CC slides:

https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/q2-2016-ir-presentation.pdf

[Fibanotch]

will be 90 by next year

[venturecapp]

Novartis, Eisai To Cooperate In Cancer Drugs Marketing In The U.S.
http://marketexclusive.com/novartis-ag-nysenvs-eisai-co-ltd-otcmktsesaly-cooperate-cancer-drugs-marketing-u-s/7648/?icd1

[DewDiligence]

NVS to run 40+ Entresto trials to boost sales:

http://finance.yahoo.com/news/novartis-launches-entresto-trials-bid-142012772.html

[stocktrademan]

$NVS recent news/filings

bearish 72.68

## source: finance.yahoo.com

$NVS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NVS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NVS/company-info
Ticker: $NVS
OTC Market Place: Not Available
CIK code: 0001114448
Company name: Novartis AG
Company website: http://www.novartis.com
Incorporated In: Switzerland

Business Description:

$NVS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$NVS extra dd links

Company name: Novartis AG
Company website: http://www.novartis.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NVS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NVS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NVS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NVS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NVS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NVS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/news - http://finance.yahoo.com/q/h?s=NVS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NVS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NVS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NVS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NVS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NVS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NVS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NVS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NVS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NVS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Novartis+AG&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Novartis+AG
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Novartis+AG&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.novartis.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.novartis.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.novartis.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NVS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NVS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NVS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NVS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NVS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001114448&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NVS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NVS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NVS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NVS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NVS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NVS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NVS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NVS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NVS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NVS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NVS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NVS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NVS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NVS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NVS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NVS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NVS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NVS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NVS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NVS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NVS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NVS



$NVS DD Notes ~ http://www.ddnotesmaker.com/NVS

[DewDiligence]

Entresto is off to a slow start: #msg-121250538.

[Penny Machine]

Looks like Offices are being Raided over Bribery Concerns
http://www.statnews.com/pharmalot/2016/02/22/novartis-south-korea-bribes-doctors/

[DewDiligence]

The 20-F annual report has been filed:

http://www.sec.gov/Archives/edgar/data/1114448/000104746916009872/a2227040z20-f.htm

[DewDiligence]

NVS 4Q15 CC slides:

https://www.novartis.com/sites/novartisemea.prod.acquia-sites.com/files/q4-2015-ir-presentation.pdf

[DewDiligence]

Alcon has become a serious drag on NVS: #msg-119762239.

[DewDiligence]

Entresto might increase risk of AMD and AD, say journal authors:

#msg-119077406

[venturecapp]

Novartis Reaffirms its CAR T Dominance

http://marketexclusive.com/novartis-reaffirms-its-car-t-dominance/1139/

[DewDiligence]

FDA approves generic Gleevec from Sun Pharma: #msg-118939751.

[DewDiligence]

FDA reviewing NVS’ 351(k) submission for Neulasta FoB: #msg-118583523.

[ProfitScout]

AVEO 8-K filing today: Novartis AV-380 Inventory Reimbursement

Link:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11012782

Novartis AV-380 Inventory Reimbursement

As previously disclosed, on August 13, 2015 (the “Effective Date”), AVEO Pharmaceuticals, Inc. (“AVEO”), entered into a License Agreement (the “License Agreement”) with Novartis International Pharmaceutical Ltd., a Bermuda corporation (“Novartis”). Under the License Agreement, AVEO granted to Novartis the exclusive right to develop and commercialize worldwide AVEO’s proprietary antibody AV-380 and related AVEO antibodies that bind to Growth Differentiation Factor 15 (GDF15) for the treatment and prevention of diseases and other conditions in all indications in humans.

Under the License Agreement, Novartis was granted the right to acquire AVEO’s inventory of clinical quality, AV-380 biological drug substance. On November 12, 2015, Novartis informed AVEO that it would exercise this right. Pursuant to the License Agreement, Novartis will reimburse AVEO $3.45 million for this existing inventory.

In addition to the $3.45 million inventory reimbursement payment, AVEO previously disclosed that under the terms of the License Agreement, AVEO received an upfront payment of $15 million and is eligible to receive potential clinical, regulatory and sales-based milestone payments as well as tiered royalties on product sales, each assuming successful advancement of the product. Novartis has responsibility under the License Agreement for the development, manufacture and commercialization of the AVEO antibodies and any resulting approved therapeutic products.

The foregoing information regarding the License Agreement does not purport to be complete and is qualified in its entirety by the full text of the License Agreement, which AVEO filed with the Securities and Exchange Commission as an exhibit to its Quarterly Report on Form 10-Q for the period ended September 30, 2015.

[TREND1]

NVS 10 MINUTES